|
1
|
Guru Murthy GS, Pemmaraju N and Atallah E:
Epidemiology and survival of blastic plasmacytoid dendritic cell
neoplasm. Leuk Res. 73:21–23. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Pagano L, Valentini CG, Pulsoni A, Fisogni
S, Carluccio P, Mannelli F, Lunghi M, Pica G, Onida F, Cattaneo C,
et al: Blastic plasmacytoid dendritic cell neoplasm with leukemic
presentation: An Italian multicenter study. Haematologica.
98:239–246. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jain A and Sweet K: Blastic plasmacytoid
dendritic cell neoplasm. J Natl Compr Canc Netw. 21:515–521. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Garnache-Ottou F, Vidal C, Biichlé S,
Renosi F, Poret E, Pagadoy M, Desmarets M, Roggy A, Seilles E,
Soret L, et al: How should we diagnose and treat blastic
plasmacytoid dendritic cell neoplasm patients? Blood Adv.
3:4238–4251. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Khoury JD, Solary E, Abla O, Akkari Y,
Alaggio R, Apperley JF, Bejar R, Berti E, Busque L, Chan JKC, et
al: The 5th edition of the World Health Organization classification
of haematolymphoid tumours: Myeloid and histiocytic/dendritic
neoplasms. Leukemia. 36:1703–1719. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Facchetti F, Cigognetti M, Fisogni S,
Rossi G, Lonardi S and Vermi W: Neoplasms derived from plasmacytoid
dendritic cells. Mod Pathol. 29:98–111. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Pemmaraju N, Kantarjian H, Sweet K, Wang
E, Senapati J, Wilson NR, Konopleva M, Frankel AE, Gupta V, Mesa R,
et al: North American blastic plasmacytoid dendritic cell neoplasm
consortium: Position on standards of care and areas of need. Blood.
141:567–578. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yun S, Chan O, Kerr D, Vincelette ND,
Idrees A, Mo Q, Sweet K, Lancet JE, Kharfan-Dabaja MA, Zhang L and
Sokol L: Survival outcomes in blastic plasmacytoid dendritic cell
neoplasm by first-line treatment and stem cell transplant. Blood
Adv. 4:3435–3442. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Taylor J, Haddadin M, Upadhyay VA, Grussie
E, Mehta-Shah N, Brunner AM, Louissaint A Jr, Lovitch SB, Dogan A,
Fathi AT, et al: Multicenter analysis of outcomes in blastic
plasmacytoid dendritic cell neoplasm offers a pretargeted therapy
benchmark. Blood. 134:678–687. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Huang L and Wang F: Primary blastic
plasmacytoid dendritic cell neoplasm: A US population-based study.
Front Oncol. 13:11781472023. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Murthy HS, Zhang MJ, Chen K, Ahmed S,
Deotare U, Ganguly S, Kansagra A, Michelis FV, Nishihori T, Patnaik
M, et al: Allogeneic hematopoietic cell transplantation for blastic
plasmacytoid dendritic cell neoplasm: A CIBMTR analysis. Blood Adv.
7:7007–7016. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tefferi A: Primary myelofibrosis: 2023
Update on diagnosis, risk-stratification, and management. Am J
Hematol. 98:801–821. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Titmarsh GJ, Duncombe AS, McMullin MF,
O'Rorke M, Mesa R, De Vocht F, Horan S, Fritschi L, Clarke M and
Anderson LA: How common are myeloproliferative neoplasms? A
systematic review and meta-analysis. Am J Hematol. 89:581–587.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cervantes F, Dupriez B, Pereira A,
Passamonti F, Reilly JT, Morra E, Vannucchi AM, Mesa RA, Demory JL,
Barosi G, et al: New prognostic scoring system for primary
myelofibrosis based on a study of the international working group
for myelofibrosis research and treatment. Blood. 113:2895–2901.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
McLornan DP, Psaila B, Ewing J, Innes A,
Arami S, Brady J, Butt NM, Cargo C, Cross NCP, Francis S, et al:
The management of myelofibrosis: A British society for haematology
guideline. Br J Haematol. 204:136–150. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tashi T, Yu J, Pandya S, Dieyi C, Scherber
R and Parasuraman S: Trends in overall mortality among US veterans
with primary myelofibrosis. BMC Cancer. 23:482023. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Thiele J and Kvasnicka HM:
Myelofibrosis-what's in a name? Consensus on definition and EUMNET
grading. Pathobiology. 74:89–96. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang N, Xu H, Li Q, Fang X, Liu J, Sui X,
Zhang L, Jiang Y and Wang X: Patients of myelodysplastic syndrome
with mild/moderate myelofibrosis and a monosomal karyotype are
independently associated with an adverse prognosis: Long-term
follow-up data. Cancer Manag Res. 12:5881–5891. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shehata M, Schwarzmeier JD, Hilgarth M,
Hubmann R, Duechler M and Gisslinger H: TGF-beta1 induces bone
marrow reticulin fibrosis in hairy cell leukemia. J Clin Invest.
113:676–685. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shenjere P, Chasty R, Chaturvedi A, Dennis
MW, Ong A, Wiseman DH and Menasce LP: E-cadherin expression in
blastic plasmacytoid dendritic cell neoplasms: An unrecognized
finding and potential diagnostic pitfall. Int J Surg Pathol.
29:289–293. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Arber DA, Orazi A, Hasserjian R, Thiele J,
Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M and Vardiman JW:
The 2016 revision to the World Health Organization classification
of myeloid neoplasms and acute leukemia. Blood. 127:2391–2405.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chen S, Zhou Y, Chen Y and Gu J: Fastp: An
ultra-fast all-in-one fastq preprocessor. Bioinformatics.
34:i884–i890. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Thorvaldsdóttir H, Robinson JT and Mesirov
JP: Integrative genomics viewer (IGV): High-performance genomics
data visualization and exploration. Brief Bioinform. 14:178–192.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Talevich E, Shain AH, Botton T and Bastian
BC: CNVkit: Genome-wide copy number detection and visualization
from targeted DNA sequencing. PLoS Comput Biol. 12:e10048732016.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ye K, Guo L, Yang X, Lamijer EW, Raine K
and Ning Z: Split-read indel and structural variant calling using
pindel. Methods Mol Biol. 1833:95–105. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tung JK, Suarez CJ, Chiang T, Zehnder JL
and Stehr H: Accurate detection and quantification of FLT3 internal
tandem duplications in clinical hybrid capture next-generation
sequencing data. J Mol Diagn. 23:1404–1413. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Adachi M, Maeda K, Takekawa M, Hinoda Y,
Imai K, Sugiyama S and Yachi A: High expression of CD56 (N-CAM) in
a patient with cutaneous CD4-positive lymphoma. Am J Hematol.
47:278–282. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Julia F, Dalle S, Duru G, Balme B, Vergier
B, Ortonne N, Vignon-Pennamen MD, Costes-Martineau V, Lamant L,
Dalac S, et al: Blastic plasmacytoid dendritic cell neoplasms:
Clinico-immunohistochemical correlations in a series of 91
patients. Am J Surg Pathol. 38:673–680. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Arber DA, Orazi A, Hasserjian RP, Borowitz
MJ, Calvo KR, Kvasnicka HM, Wang SA, Bagg A, Barbui T, Branford S,
et al: International consensus classification of myeloid neoplasms
and acute leukemias: Integrating morphologic, clinical, and genomic
data. Blood. 140:1200–1228. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kong LZ, Li J, Wang RC, Kang L, Wei Q and
Li Y: Simultaneous follicular lymphoma and myelofibrosis: Report of
a case with review of the literature. Onco Targets Ther.
14:4551–4559. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Amel Riazat-Kesh YJR, Maraveyas A, Martin
L and Tremblay D: An overlooked mimic? Autoimmune myelofibrosis-A
scoping review of the literature. Eur J Haematol. 111:706–714.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Beird HC, Khan M, Wang F, Alfayez M, Cai
T, Zhao L, Khoury J, Futreal PA, Konopleva M and Pemmaraju N:
Features of non-activation dendritic state and immune deficiency in
blastic plasmacytoid dendritic cell neoplasm (BPDCN). Blood Cancer
J. 9:992019. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Tabata R, Tabata C, Nagai T and Yasumizu
R: Follicular lymphoma with prominent fibrosis complicated by
peripheral eosinophilia. Ann Hematol. 91:965–967. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Scherber RM and Mesa RA: Managing
myelofibrosis (MF) that ‘blasts’ through: Advancements in the
treatment of relapsed/refractory and blast-phase MF. Hematology Am
Soc Hematol Educ Program. 2018:118–126. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Okabe S, Miyazawa K, Iguchi T, Sumi M,
Takaku T, Ito Y, Ito Y, Kimura Y, Serizawa H, Mukai K and Ohyashiki
K: Peripheral T-cell lymphoma together with myelofibrosis with
elevated plasma transforming growth factor-beta1. Leuk Lymphoma.
46:599–602. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Tsutsui M, Yasuda H, Ota Y and Komatsu N:
Splenic marginal zone lymphoma with prominent myelofibrosis
mimicking triple-negative primary myelofibrosis. Case Rep Oncol.
12:834–837. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Matsunaga T, Takemoto N, Miyajima N, Okuda
T, Nagashima H, Sato T, Terui T, Sasaki H, Ohmi N, Hirayama Y, et
al: Splenic marginal zone lymphoma presenting as myelofibrosis
associated with bone marrow involvement of lymphoma cells which
secrete a large amount of TGF-beta. Ann Hematol. 83:322–325. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Nakajima H and Kunimoto H: TET2 as an
epigenetic master regulator for normal and malignant hematopoiesis.
Cancer Sci. 105:1093–1099. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Abdel-Wahab O, Mullally A, Hedvat C,
Garcia-Manero G, Patel J, Wadleigh M, Malinge S, Yao J, Kilpivaara
O, Bhat R, et al: Genetic characterization of TET1, TET2, and TET3
alterations in myeloid malignancies. Blood. 114:144–147. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Delhommeau F, Dupont S, Della Valle V,
James C, Trannoy S, Massé A, Kosmider O, Le Couedic JP, Robert F,
Alberdi A, et al: Mutation in Tet2 in myeloid cancers. N Eng J Med.
360:2289–2301. 2009. View Article : Google Scholar
|
|
41
|
Vainchenker W and Kralovics R: Genetic
basis and molecular pathophysiology of classical myeloproliferative
neoplasms. Blood. 129:667–679. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ostrander EL, Kramer AC, Mallaney C, Celik
H, Koh WK, Fairchild J, Haussler E, Zhang CRC and Challen GA:
Divergent effects of Dnmt3a and Tet2 mutations on hematopoietic
progenitor cell fitness. Stem Cell Reports. 14:551–560. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Schubbert S, Shannon K and Bollag G:
Hyperactive Ras in developmental disorders and cancer. Nat Rev
Cancer. 7:295–308. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Ohguchi Y and Ohguchi H: Dis3: The
enigmatic gene in multiple myeloma. Int J Mol Sci. 24:40792023.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Chen XL, Hong LL, Wang KL, Liu X, Wang JL,
Lei L, Xu ZY, Cheng XD and Ling ZQ: Deregulation of CSMD1 targeted
by microRNA-10b drives gastric cancer progression through the NF-κB
pathway. Int J Biol Sci. 15:2075–2086. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Damm F, Chesnais V, Nagata Y, Yoshida K,
Scourzic L, Okuno Y, Itzykson R, Sanada M, Shiraishi Y, Gelsi-Boyer
V, et al: BCOR and BCORL1 mutations in myelodysplastic syndromes
and related disorders. Blood. 122:3169–3177. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Sportoletti P, Sorcini D and Falini B:
BCOR gene alterations in hematologic diseases. Blood.
138:2455–2468. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Badaat I, Mirza S, Padron E, Sallman D,
Komrokji R, Song J and Hussaini MO: Concurrent mutations in other
epigenetic modulators portend better prognosis in BCOR-mutated
myelodysplastic syndrome. J Clin Pathol. 73:209–212. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Elling C, Erben P, Walz C, Frickenhaus M,
Schemionek M, Stehling M, Serve H, Cross NC, Hochhaus A, Hofmann
WK, et al: Novel imatinib-sensitive PDGFRA-activating point
mutations in hypereosinophilic syndrome induce growth factor
independence and leukemia-like disease. Blood. 117:2935–2943. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Abdulbaki R, DeRosa PA, Mobarek D, Liu ML
and Nava VE: Novel PDGFRA mutation in blastic plasmacytoid
dendritic cell neoplasm; possible therapeutic implications. Br J
Haematol. 197:82022. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Collin M and Bigley V: Human dendritic
cell subsets: An update. Immunology. 154:3–20. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Verstovsek S, Manshouri T, Pilling D,
Bueso-Ramos CE, Newberry KJ, Prijic S, Knez L, Bozinovic K, Harris
DM, Spaeth EL, et al: Role of neoplastic monocyte-derived
fibrocytes in primary myelofibrosis. J Exp Med. 213:1723–1740.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Tremblay D and Mascarenhas J: Next
generation therapeutics for the treatment of myelofibrosis. Cells.
10:10342021. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Werth VP, Furie RA, Romero-Diaz J, Navarra
S, Kalunian K, van Vollenhoven RF, Nyberg F, Kaffenberger BH,
Sheikh SZ, Radunovic G, et al: Trial of anti-BDCA2 antibody
litifilimab for cutaneous lupus erythematosus. N Engl J Med.
387:321–331. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Ceribelli M, Hou ZE, Kelly PN, Huang DW,
Wright G, Ganapathi K, Evbuomwan MO, Pittaluga S, Shaffer AL,
Marcucci G, et al: A druggable TCF4- and BRD4-dependent
transcriptional network sustains malignancy in blastic plasmacytoid
dendritic cell neoplasm. Cancer Cell. 30:764–778. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Montero J, Stephansky J, Cai T, Griffin
GK, Cabal-Hierro L, Togami K, Hogdal LJ, Galinsky I, Morgan EA,
Aster JC, et al: Blastic Plasmacytoid dendritic cell neoplasm is
dependent on BCL2 and sensitive to venetoclax. Cancer Discov.
7:156–164. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Sapienza MR, Abate F, Melle F, Orecchioni
S, Fuligni F, Etebari M, Tabanelli V, Laginestra MA, Pileri A,
Motta G, et al: Blastic plasmacytoid dendritic cell neoplasm:
Genomics mark epigenetic dysregulation as a primary therapeutic
target. Haematologica. 104:729–737. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Azad F, Zhang J, Miranda CJ and Gravina M:
Venetoclax and Azacitidine in the treatment of blastic plasmacytoid
dendritic cell neoplasm refractory to conventional therapy. Cureus.
14:e331092022.PubMed/NCBI
|
|
59
|
Samhouri Y, Ursu S, Dutton N, Tanvi V and
Fazal S: Tagraxofusp followed by combined azacitidine and
venetoclax in blastic plasmacytoid dendritic cell neoplasm: A case
report and literature review. J Oncol Pharm Pract. 27:990–995.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Togami K, Pastika T, Stephansky J, Ghandi
M, Christie AL, Jones KL, Johnson CA, Lindsay RW, Brooks CL, Letai
A, et al: DNA methyltransferase inhibition overcomes diphthamide
pathway deficiencies underlying CD123-targeted treatment
resistance. J Clin Invest. 129:5005–5019. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Moore AR, Rosenberg SC, McCormick F and
Malek S: RAS-targeted therapies: Is the undruggable drugged? Nat
Rev Drug Discov. 19:533–552. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Lyman GH, Poniewierski MS and Culakova E:
Risk of chemotherapy-induced neutropenic complications when
treating patients with non-Hodgkin lymphoma. Expert Opin Drug Saf.
15:483–492. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Dinan MA, Hirsch BR and Lyman GH:
Management of chemotherapy-induced neutropenia: Measuring quality,
cost, and value. J Natl Compr Canc Netw. 13:e1–e7. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Epstein RS, Aapro MS, Basu Roy UK, Salimi
T, Krenitsky J, Leone-Perkins ML, Girman C, Schlusser C and
Crawford J: Patient burden and real-world management of
chemotherapy-induced myelosuppression: Results from an online
survey of patients with solid tumors. Adv Ther. 37:3606–3618. 2020.
View Article : Google Scholar : PubMed/NCBI
|
